1. To review the management of resectable gastroesophageal adenocarcinoma

  2. To discuss a phase II trial of neoadjuvant pembrolizumab in resectable cT1b-T2N0 gastroesphageal adenocarcinoma

  3. To describe a phase I trial of 5-FU, nab-paclitaxel, and irinotecan (FOLFIRABRAX) with UGT1A1 genotype-guided dosing in advanced GI malignancies

Session date: 
09/10/2018 - 12:00pm to 1:00pm CDT
5841 South Maryland Avenue
MC2115 HemOnc Conference Room E-215
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Smita Joshi, MD